title: Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
abstract: We assessed the efficacy and adverse effects of febuxostat in male hyperuricemia patients.
  
  
  
  This was a 12-week, multicenter, open-label, uncontrolled study. The enrolled subjects were 89 hyperuricemic male patients (12 overexcretors, 56 normal excretors, and 21 underexcretors). The endpoint was percent change in serum urate level.
  
  
  
  The concentration of urate in serum before and 12 weeks after beginning administration of febuxostat in the overexcretors was 9.34 ± 1.48 and 5.59 ± 1.17 mg/dl, respectively, while those were 8.59 ± 1.24 and 5.41 ± 1.35 mg/dl, respectively, in the normal excretors, and 8.29 ± 1.01and 5.11 ± 1.71 mg/dl, respectively, in the underexcretors. After 12 weeks, the rate of change in serum urate after beginning administration of febuxostat was - 0.384 ± 0.186 in the overexcretors, - 0.368 ± 0.128 in the normal excretors, and - 0.365 ± 0.217 in the underexcretors, with no significant differences among them. A common adverse event related to febuxostat was gout flare.
  
  
  
  Febuxostat effectively reduced the concentration of urate in serum in hyperuricemic patients regardless of the level of uric acid excreted in urine without severe adverse effects.
authors: a Department of Diabetes , Endocrinology and Metabolism, Hyogo College of Medicine , Hyogo , Japan.
authors: Tetsuya
authors: T
authors: Yamamoto
authors: Yuji
authors: Y
authors: Hidaka
authors: Masaaki
authors: M
authors: Inaba
authors: Eiji
authors: E
authors: Ishimura
authors: Hiroshi
authors: H
authors: Ooyama
authors: Hirokazu
authors: H
authors: Kakuda
authors: Yuji
authors: Y
authors: Moriwaki
authors: Kenshi
authors: K
authors: Higami
authors: Akira
authors: A
authors: Ohtawara
authors: Tatsuo
authors: T
authors: Hosoya
authors: Hazime
authors: H
authors: Nishikawa
authors: Atsuo
authors: A
authors: Taniguchi
authors: Takanori
authors: T
authors: Ueda
authors: Takahiro
authors: T
authors: Yamauchi
authors: Shin
authors: S
authors: Fujimori
authors: Ikuo
authors: I
authors: Mineo
authors: Hisashi
authors: H
authors: Yamanaka
mesh_terms: D000328:Adult; D000069465:Febuxostat / Q000627:therapeutic use*; D005260:Female; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
chemical_list: D006074:Gout Suppressants; D000069465:Febuxostat; D014527:Uric Acid
keywords: Febuxostat; Gout; Gout flare; Hyperuricemia; Uric acid